Molgramostim + Placebo + Molgramostim Open-label

Phase 3Active

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Autoimmune Pulmonary Alveolar Proteinosis

Conditions

Autoimmune Pulmonary Alveolar Proteinosis

Trial Timeline

May 19, 2021 → May 30, 2027

NCT ID

NCT04544293

About Molgramostim + Placebo + Molgramostim Open-label

Molgramostim + Placebo + Molgramostim Open-label is a phase 3 stage product being developed by Savara for Autoimmune Pulmonary Alveolar Proteinosis. The current trial status is active. This product is registered under clinical trial identifier NCT04544293. Target conditions include Autoimmune Pulmonary Alveolar Proteinosis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04544293	Phase 3	Active	May 19, 2021	May 30, 2027	Autoimmune Pulmonary Alveolar Proteinosis

Competing Products

20 competing products in Autoimmune Pulmonary Alveolar Proteinosis

See all competitors

Product	Company	Stage	Hype Score
Satralizumab	Chugai Pharmaceutical	Phase 3	77
SHR0302 quick release tablets + SHR0302 sustained-release tablets	Jiangsu Hengrui Medicine	Phase 1	33
HR19042 Capsule, Tarpeyo®, Budenofalk®	Jiangsu Hengrui Medicine	Phase 1	33
HR19042 Capsules	Jiangsu Hengrui Medicine	Phase 2	52
Enteric-coated Mycophenolate Sodium	Novartis	Phase 3	77
Ianalumab + Placebo	Novartis	Phase 3	77
VAY736	Novartis	Phase 2/3	65
remibrutinib	Novartis	Phase 1	33
RO7049665	Roche	Phase 2	52
rituximab (Mabthera®) + Placebo	Roche	Phase 3	77
NovoMix 30 + Tablet treatment	Novo Nordisk	Pre-clinical	22
Anakinra 100Mg/0.67Ml Inj Syringe (Period 1) + Placebo injection (Period 1) + Anakinra 100Mg/0.67Ml Inj Syringe (Period 2) + Placebo injection (Period 2)	Swedish Orphan Biovitrum	Phase 2	51
branebrutinib + abatacept + branebrutinib placebo	Bristol Myers Squibb	Phase 2	51
BMS-986165	Bristol Myers Squibb	Phase 1	32
Nivolumab	Bristol Myers Squibb	Phase 1	32
Fludarabine + Cyclophosphamide + Tocilizumab	Bristol Myers Squibb	Phase 1	32
BMS-986165 + Rosuvastatin	Bristol Myers Squibb	Phase 1	32
SAR445088	Sanofi	Phase 1	32
BIVV020	Sanofi	Phase 1	32
rilzabrutinib	Sanofi	Phase 2	51

Other Products from Savara

MolgramostimPhase 3

Vancomycin inhalation powder + Placebo inhalation powder + Vancomycin inhalation powderPhase 3

MolgramostimPhase 3

Vancomycin hydrochloride inhalation powder + Placebo inhalation powderPhase 2

Molgramostim + PlaceboPhase 2